Key Points
Investors are shifting away from high-risk technology stocks to more stable sectors such as healthcare and retail due to recent market uncertainties, including concerns over geopolitical issues and U.S. economic growth. This trend has resulted in a significant uptick in stock prices for companies like Moderna and Target.
Moderna (NASDAQ: MRNA) has surged nearly 70% year-to-date after re-establishing itself in the market with a diversified vaccine portfolio and a forecast of 10% revenue growth. The company hopes to revive growth through seasonal vaccines and treatments for rare diseases. Meanwhile, Target (NYSE: TGT) has seen its stock rise over 20% in 2023, driven by a $2 billion investment plan aimed at improving store performance and customer experience under new CEO Michael Fiddelke.
